COMP <GO>
DXPE vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
DXP Enterprises Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: DXPE 4
— TMO 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: DXPE
LAST: $176.29 (+5.13%) • MKT CAP: $2.74B
roic
13.80%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXPE VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXPE | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 31.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 13.80% | 9.30% | +4.50 | DXPE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.4x | 30.4x | -15.00 | DXPE | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 2.40% | -0.43 | TMO | /fcf-yield <GO> |
| Operating Margin | 8.80% | 17.40% | -8.60 | TMO | /operating-margins <GO> |
| Net Profit Margin | 4.40% | 15.10% | -10.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | 3.90% | +8.00 | DXPE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.78 | 4.50 | -0.72 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.6 | 62.9 | -14.27 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.6x | 36.3x | -7.70 | DXPE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.74B | $262.22B | -$259.48B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXPE REV | TMO REV | DXPE GROSS % | TMO GROSS % | DXPE FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.02B | $44.56B | 31.5% | — | $54.0M | $6.29B |
| FY 2024 | $1.80B | $42.88B | 30.9% | — | $77.1M | $7.27B |
| FY 2023 | $1.68B | $42.86B | — | — | $106.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXPE // BETA —
TMO // BETA 0.94